+Compare
BCYC
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
758.9M

BCYC Bicycle Therapeutics plc Forecast, Technical & Fundamental Analysis

a holding company, which engages in the development of biopharmaceuticals.

Industry Biotechnology
GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for BCYC with price predictions
08:00 PM EDT Jun 01, 2023

Momentum Indicator for BCYC turns positive, indicating new upward trend

BCYC saw its Momentum Indicator move above the 0 level on April 28, 2023. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 72 similar instances where the indicator turned positive. In of the 72 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BCYC just turned positive on June 02, 2023. Looking at past instances where BCYC's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .

BCYC moved above its 50-day moving average on May 05, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BCYC crossed bullishly above the 50-day moving average on May 10, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BCYC advanced for three days, in of 213 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 118 cases where BCYC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BCYC moved out of overbought territory on May 23, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 46 cases where BCYC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCYC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BCYC broke above its upper Bollinger Band on May 12, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BCYC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.121) is normal, around the industry mean (25.150). P/E Ratio (0.000) is within average values for comparable stocks, (123.096). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.331). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (48.544) is also within normal values, averaging (308.288).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCYC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.12B. The market cap for tickers in the group ranges from 365 to 350.31B. NONOF holds the highest valuation in this group at 350.31B. The lowest valued company is CLAZF at 365.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 31%. EFTR experienced the highest price growth at 77%, while BLCM experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -3%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

BCYC is expected to report earnings to fall 14.62% to -111 cents per share on August 03

Bicycle Therapeutics plc BCYC Stock Earnings Reports
Q2'23
Est.
$-1.11
Q1'23
Missed
by $0.22
Q4'22
Beat
by $0.05
Q3'22
Missed
by $0.07
Q2'22
Missed
by $0.05
The last earnings report on May 04 showed earnings per share of -129 cents, missing the estimate of -108 cents. With 181.31K shares outstanding, the current market capitalization sits at 758.90M.
A.I. Advisor
published General Information

General Information

a holding company, which engages in the development of biopharmaceuticals.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Granta Park, Great Abington
Phone
+44 1223261503
Employees
236
Web
https://www.bicycletherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EAASX29.010.69
+2.44%
Eaton Vance Atlanta Capital SMID-Cap A
CSFAX49.210.98
+2.03%
Cohen & Steers Global Realty A
GWSAX15.250.27
+1.80%
Gabelli Focused Gr and Inc A
IYVYX20.800.36
+1.76%
Delaware Ivy Value Y
RGFTX8.560.09
+1.06%
Russell Inv Global Infrastructure M

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with CRNX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+3.95%
CRNX - BCYC
45%
Loosely correlated
+0.73%
ALXO - BCYC
45%
Loosely correlated
+12.74%
VXRT - BCYC
45%
Loosely correlated
+0.80%
AGIO - BCYC
44%
Loosely correlated
+1.32%
INSM - BCYC
44%
Loosely correlated
+1.56%
More

Groups containing BCYC

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+3.95%
europe
(undefined stocks)
36%
Loosely correlated
+2.04%